Compositions and methods for detecting and treating colorectal cancer
The present invention relates to compositions and methods for the detecting, treating, and empirically investigating the interaction between a subject's immune system and cancer stem cells. In particular, the present invention provides compositions and methods for using IL-22 cytokine signaling and/or downstream targets of IL-22 cytokine signaling (e.g., STAT3, DOT1L, SUZ12, EED) in the diagnosis, treatment, and empirical investigation of cancers characterized with cancer stem cells activated through IL-22 cytokine signaling.
1. A method of treating colorectal cancer characterized with activated cancer stem cells in a subject, the method comprising
administering to said subject an agent that down regulates the expression, amount or activity of DOT1L, wherein said administering inhibits cancer stem cell activation within colorectal cancer cells,
wherein the agent is a DOT1L inhibiting agent, wherein the DOT1L inhibiting agent is
a pharmaceutical composition comprising EPZ5676.